Go Deep
LB Pharmaceuticals Inc
LB Pharmaceuticals Inc Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,490 | 347.9 | 3.38 | 0.02 | 3,313.18 |
| Oct 2026 | 20,615 | 340.0 | 3.30 | 0.02 | 3,228.21 |
| Oct 2026 | 20,189 | 366.9 | 3.56 | 0.02 | 3,484.12 |
| Oct 2026 | 20,181 | 367.4 | 3.57 | 0.02 | 3,479.83 |
| Oct 2026 | 19,854 | 388.1 | 3.77 | 0.02 | 3,679.82 |
| Oct 2026 | 19,507 | 410.0 | 3.98 | 0.02 | 3,887.47 |
| Oct 2026 | 19,787 | 392.3 | 3.81 | 0.02 | 3,710.46 |
| Oct 2026 | 19,757 | 394.2 | 3.83 | 0.02 | 3,720.89 |
| Oct 2026 | 19,866 | 387.3 | 3.76 | 0.02 | 3,670.91 |
LB Pharmaceuticals Inc Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -51,603,000.0 | -19,054,000.0 | -11,472,000.0 | -3,556,000.0 |
| EPS | -1.7 | -0.7 | -0.5 | -0.6 |
LB Pharmaceuticals Inc Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -25,205,000.0 | -63,102,000.0 | -6,275,000.0 | -14,348,000.0 |
| EPS | -3.1 | -17.8 | -1.8 | -4.1 |
LB Pharmaceuticals Inc Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 312,934,000.0 | 33,534,000.0 | 45,657,000.0 | 21,492,000.0 |
| Total Liabilities | 11,624,000.0 | 128,088,000.0 | 80,130,000.0 | 50,304,000.0 |
| Total Equity | 301,310,000.0 | -94,554,000.0 | -34,473,000.0 | -28,812,000.0 |
Owes vs Owns
LB Pharmaceuticals Inc owed $0.08 for every $1 it owned in Jun 2026, down from $2.34 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.08× | 0.04× | 3.82× | 1.76× | 2.34× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
LB Pharmaceuticals Inc Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 94.3%Fixed assets (tangible) 1.2%Other assets 4.5%
How it's funded — Dec 2025
Long-term debt 0.9%Payables 0.7%Other liabilities 1.9%Shareholders' equity 96.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 295.2 | 28.0 | 43.3 | 21.4 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 3.7 | 4.2 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 14.0 | 1.4 | 2.3 | 0.1 |
| Liabilities & equity | ||||
| Short-term debt | 0.7 | 0.5 | 0.0 | 0.0 |
| Long-term debt | 2.8 | 3.2 | 0.0 | 24.1 |
| Payables | 2.1 | 2.3 | 1.4 | 0.2 |
| Other liabilities | 5.9 | 122.1 | 78.7 | 26.0 |
| Shareholders' equity | 301.3 | -94.6 | -34.5 | -28.8 |
| Net tangible assets | 301.3 | -94.6 | -34.5 | -28.8 |
LB Pharmaceuticals Inc Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -35,208,000.0 | -53,052,000.0 | -12,094,000.0 | -2,728,000.0 |
| Investing Activities | -39,887,000.0 | 23,234,000.0 | -28,010,000.0 | 123,000.0 |
| Financing Activities | 302,562,000.0 | 38,315,000.0 | 33,679,000.0 | 22,962,000.0 |